Area of research
Epidemiology · Hepatology
Research interest
Research focused on Hepatocellular carcinoma and Microbiome, with related work in Sorafenib, Apatinib, Mesenchymal stem cell. Notable publications include 'Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma', 'Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial', and 'Mesenchymal Stem Cell/Red Blood Cell-Inspired Nanoparticle Therapy in Mice with Carbon Tetrachloride-Induced Acute Liver Failure'.
A machine learning model for mortality prediction in patients with severe fever with thrombocytopenia syndrome: a prospective, multicenter cohort study
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial
Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study
Mechanistic insights into post-translational modifications in hepatic fibrosis: pathogenic roles and therapeutic potentials
SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial.
The correlation between gut microbiome and atrial fibrillation: pathophysiology and therapeutic perspectives
Nanosecond pulse effectively ablated hepatocellular carcinoma with alterations in the gut microbiome and serum metabolites
Development of a model by LASSO to predict hospital length of stay (LOS) in patients with the SARS-Cov-2 omicron variant
Serum metabolome alterations in patients with early nonalcoholic fatty liver disease
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
Human microbiome is a diagnostic biomarker in hepatocellular carcinoma
A novel predicted model for hypertension based on a large cross-sectional study
Role of cyclin‐dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway
Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma
Mesenchymal Stem Cell/Red Blood Cell-Inspired Nanoparticle Therapy in Mice with Carbon Tetrachloride-Induced Acute Liver Failure
Simpler Novel Non-Invasive Program Score for Stage-by-Stage Diagnosis of Liver Fibrosis in Untreated Patients with Chronic Hepatitis B: A Multicenter Prospective Study